The period for CME/CE credit for this activity has expired.


Cardiometabolic Risk Reduction in the Metabolic Syndrome and Type 2 Diabetes


Applied Practical Learning (APL) is intended to assess behavioral change as a result of participating in a continuing education activity. There are 2 sections in this activity. Both sections must be completed to receive credit.

After completing both sections and submitting them as directed, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you for your participation.


Cardiometabolic Risk Reduction in the Metabolic Syndrome and Type 2 Diabetes Applied Practical Learning Component

Term of Approval

Release Date: December 2007

Expiration Date: December 31, 2008

Activity Overview

Glucose intolerance, dyslipidemia, hypertension, and obesity are hallmark cardiometabolic risk factors included in many definitions of the metabolic syndrome, sometimes known as prediabetes. Type 2 diabetes, with its crushing burden of morbidity and mortality, can be precipitated by further weight gain in individuals with metabolic syndrome. Although multiple effective treatments currently exist to ameliorate 3 of the 4 cardiometabolic risk factors, obesity management is complicated by a lack of tolerable, effective pharmacologic treatments. A new class of drugs, called endocannabinoid blockers, have pleiotropic effects on cardiometabolic risk in the metabolic syndrome and type 2 diabetes. This activity will assess the participant's willingness to change practice behavior based on the research and education presented in the satellite broadcast activity by the same title.

Intended Audience

This activity was developed for physicians, nurses, and pharmacists involved in the management of patients with obesity and cardiometabolic risk factors.

Method of Participation and Obtaining CME Credit

CME credit is offered upon successful completion of the demographic and case study sections of this activity. Certificates will be issued electronically immediately upon completion of submitting both components.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

•  Examine the impact of obesity, dyslipidemia, hypertension and type 2 diabetes on the cardiovascular morbidity and mortality

•  Discuss the endocannabinoid system and other energy-regulating mechanisms and their potential roles in modifying cardiometabolic risk factors

•  Explore patient care considerations and therapeutic options for modifying cardiometabolic risk factors in overweight or obese patients, including those with type 2 diabetes

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Summit Institute of Knowledge, Inc., and International Medical Press (IMP). Summit Institute of Knowledge, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Summit Institute of Knowledge, Inc., designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit . Physicians should only claim credit commensurate with the extent of their participation in the activity.


In compliance with the ACCME, it is the policy of Summit Institute of Knowledge, Inc., and IMP to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, CME provider staff, faculty and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months . Summit also requires that faculty identify and reference off-label product or investigational uses of pharmaceutical and medical device products.

All conflicts of interest have been mitigated and resolved through the use of an external peer review process.


F. Xavier Pi-Sunyer , MD , MPH

Advisory Board: Amylin Pharmaceuticals, Eli Lilly and Company, McNeil Nutritionals, Novo Nordisk Inc., sanofi-aventis, Schering Plough, Weight Watchers

Research: Merck & Co, Inc., Novartis, sanofi-aventis, Wrigley

Frank Svec, MD, PhD

Consultant: Pfizer Inc, Novartis


All staff of Summit Institute of Knowledge, Inc., and IMP in a position to influence content have filed statements of disclosure with the CME provider. Any conflicts of interest were identified and resolved prior to their involvement in planning this activity. These disclosures are available for review by contacting Amy Groves at 404-443-1596 or e-mail at

Summit Institute of Knowledge, Inc., and IMP staffs have disclosed no conflicts of interest.


This activity is designed for healthcare professionals for educational purposes. Information and opinions offered by the faculty represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While Summit Institute of Knowledge, Inc., makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Commercial Support Acknowledgment

This activity is supported by an educational grant from sanofi-aventis.

Applied Practical Learning (APL) Section.

  • PLEASE NOTE: You can click on each section to get a look at this activity but you must be signed in to participate and receive CME credit. New to Click here to register.
  • Demographic Questionnaire - This portion of the activity allows us to evaluate the types of healthcare professionals who are participating in the activity. This information will also be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer. After completing this section, you will be directed to the patient case study section.
  • Patient Case Study - This portion of the activity will help us determine how you will apply the information used in the CME activity to your clinical practice by presenting a hypothetical patient and asking questions about your treatment approach for this patient. When answering these questions, please try to relate the patient to a specific patient in your practice with the same characteristics. Additional information, such as graphs and figures to help you determine the answer, is provided for some questions and may be enlarged by clicking on the image.